Vera Therapeutics/$VERA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Ticker
- $VERA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 362
- Headquarters
- Brisbane, United States
- Website
- veratx.com
VERA Metrics
BasicAdvanced
$2B
-
-$5.91
1.19
-
Price and volume
Market cap
$2B
Beta
1.19
52-week high
$56.05
52-week low
$26.38
Average daily volume
1.7M
Financial strength
Current ratio
7.912
Quick ratio
7.147
Long term debt to equity
0.23
Total debt to equity
0.23
Interest coverage (TTM)
-57.40%
Profitability
EBITDA (TTM)
-426.3
Gross margin (TTM)
67.93%
Net profit margin (TTM)
-4,041.19%
Operating margin (TTM)
-4,160.07%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-54.35%
Return on equity (TTM)
-113.46%
Valuation
Price to revenue (TTM)
192.133
Price to book
6.1
Price to tangible book (TTM)
6.5
Price to free cash flow (TTM)
-5.241
Free cash flow yield (TTM)
-19.08%
Free cash flow per share (TTM)
-5.361
Growth
Earnings per share change (TTM)
47.79%
3-year earnings per share growth (CAGR)
30.36%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Analyst projections of the future price of Vera Therapeutics stock.
Bulls say / Bears say
In the 428-patient ORIGIN 3 trial, atacicept cut annualised eGFR decline to 0.6 mL/min/1.73m² from 5.6 on placebo and reduced kidney-progression events. That points to a meaningful benefit on kidney function, not just a change in proteinuria. (New England Journal of Medicine)
TRUTAKNA has FDA accelerated approval and the US launch is generating early demand: Vera reported about 700 patient start forms and $10.3 million in third-quarter product revenue. This gives the company a commercial product and a first foothold in a sizeable patient market. (Vera Therapeutics)
Atacicept may have growth potential beyond its first US indication: Vera reported interim PIONEER results from adult IgA nephropathy and primary membranous nephropathy cohorts, and plans an EU marketing application in 2027. Success in further indications or regions could broaden the opportunity, though these remain development and regulatory steps. (Vera Therapeutics)
The launch is still at an early stage: third-quarter revenue was $10.3 million, and patient start forms do not yet show how many patients will stay on treatment or how quickly sales can scale. Commercial adoption remains unproven. (Vera Therapeutics)
Vera reported a $93.7 million quarterly net loss and $305.9 million of operating cash use over the first nine months of 2026. It expects continued losses, so further borrowing or share issuance could weigh on flexibility or dilute shareholders. (U.S. Securities and Exchange Commission)
TRUTAKNA still has accelerated, not full, approval; FDA review of Vera’s supplemental application is outstanding, with a decision expected in mid-2027. A delay or an unfavourable review could leave the product’s approval status unresolved for longer. (Vera Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
Upcoming events
No upcoming events
VERA News
AllArticlesVideos
Funds containing VERA
Fund name | Fund size | $VERA weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | $9.1B | 0.20% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.14% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.14% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.